BIOND health

BIOND the booth: why is pharma only investing in m²?

Pharma spends most of its congress budget on a few hundred square metres of exhibition floor. We asked a room of pharma leaders, and a practising doctor, whether that is where HCP engagement really happens.

In partnership withSpace & Time

← All events

Closed-door executive roundtableBFI Southbank, London

Aftermovie, with subtitles

One European dermatology congress
  1. 38,000dermatologists in Europe
  2. 17,000congress attendees
  3. 500booth visitors
  4. 233symposium attendees

The booth met 1.3% of Europe's dermatologists. Where were the other 98.7%?

Pharma leaders, behavioural and compliance experts and a few selective agency voices sat around one table with a special guest: Dr Dev Gakhar, an NHS resident doctor who turns complex NHS policy into content that makes sense. Most pharma conversations about HCPs happen without an HCP in the room. This one had him challenging assumptions in real time.

We started with the question most congress plans skip: why do HCPs actually go? Not to engage with brand activation, but to make sense of new evidence, validate their thinking with peers and build confidence in their decisions. Yet congress plans stay booth-first, stop when the event days end and offer no journey to the HCPs who never came. The insights became our white paper, Congress beyond the booth.

What the room took away

  • HCPs come to make sense of evidence, validate it with peers and decide with confidence, not to visit booths
  • Most engagement is missed before and after the event, and with the HCPs who never come
  • Move from short-term spikes to sustained impact: prime before, amplify during, build journeys after

A sample of the pharma companies around the table

  • Astellas
  • Accord Healthcare
  • Bayer

Want to bring this conversation to your team?

Book a black belt session
45 minutes with Yacin M. Free. On video.Or write to yacin.m@biond.health

Or send a message